Table 2.
Adjusted odds ratios (aOR) and 95% confidence intervals (CI) for venous thromboembolism (VTE)
| Casesn = 3316 | Controlsn = 32 617 | Crude OR (95% CI) | aOR (95% CI)# | |
|---|---|---|---|---|
| Treatment assessed in the 28 days preceding ID * | ||||
| Epoetins (reference group: past treatment with transfusion and/or epoetin) | 96 (2.9%) | 897 (2.8%) | 1.41 (1.13, 1.75) | 1.31 (1.03, 1.65) |
| Transfusions (reference group: past treatment with transfusion and/or epoetin) | 1168 (35.2%) | 9274 (28.4%) | 2.62 (2.30, 2.98) | 2.33 (2.03, 2.66) |
| Epoetins and transfusions (reference group: past treatment with transfusion and/or epoetin) | 22 (0.7%) | 104 (0.3%) | 3.01 (1.88, 4.81) | 2.24 (1.34, 3.77) |
| Co‐morbidities assessed in the year before cohort entry *, † | ||||
| History of VTE | 657 (19.8%) | 482 (1.5%) | 14.76 (12.79, 17.03) | |
| Obesity | 810 (24.4%) | 5588 (17.1%) | 1.53 (1.39, 1.69) | |
| Metastatic solid tumour | 1507 (45.5%) | 11 152 (34.2%) | 1.35 (1.24, 1.46) | |
| Other treatment assessed in the 90 days preceding ID *, † | ||||
| Surgery | 1712 (51.6%) | 14 136 (43.3%) | 1.83 (1.67, 2.01) | |
| Chemotherapy | 1613 (48.6%) | 11 796 (36.2%) | 1.65 (1.50, 1.82) | |
| Other medication associated with increased VTE risk | 1019 (30.7%) | 7770 (23.8%) | 1.22 (1.11, 1.34) | |
| Antithrombotic medication | 1064 (32.1%) | 5962 (18.3%) | 1.30 (1.18, 1.43) |
Matching was performed for age, gender and SHI.
It was adjusted for history of VTE, obesity, metastatic solid tumour, surgery, chemotherapy, other medication associated with increased VTE risk (Table S3), antithrombotic medication (Table S4) coronary artery disease/chronic ischaemic heart disease, arterial hypertension, dyslipidaemia, diabetes mellitus, myocardial infarction and angina pectoris.
Reference group were patients with no such co‐morbidities and patients with no such treatment, respectively.
Past treatment with epoetin and/or transfusion means that the last dispensation of epoetin or administration of transfusion was longer than 28 days before the index date.
ID index date; SHI statutory health insurance.
Only variables with statistically significant increased risks are presented (further variables tested: coronary artery disease/chronic ischaemic heart disease, arterial hypertension, dyslipidaemia, diabetes mellitus, myocardial infarction, angina pectoris).